Who are FS MDPI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): No Lutinus + transfer day 6, Methylene blue (1%), B4, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa, Low dose oxelidine group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fs-mdpi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

FS MDPI — Competitive Intelligence Brief

FS MDPI (FS MDPI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine oxidase inhibitor (MAOI). Area: Psychiatry/Neurology.

phase 3 Monoamine oxidase inhibitor (MAOI) Monoamine oxidase Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

FS MDPI (FS MDPI) — Teva Branded Pharmaceutical Products R&D, Inc.. FS MDPI is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FS MDPI TARGET	FS MDPI	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Monoamine oxidase inhibitor (MAOI)	Monoamine oxidase
No Lutinus + transfer day 6	No Lutinus + transfer day 6	Anja Bisgaard Pinborg	marketed	monoamine oxidase inhibitor	monoamine oxidase A and B
Methylene blue (1%)	Methylene blue (1%)	University Hospital, Strasbourg, France	marketed	Redox agent; monoamine oxidase inhibitor	Mitochondrial electron transport chain; monoamine oxidase; methemoglobin reductase
B4	B4	Breath of Life International Pharma Ltd	marketed	monoamine oxidase inhibitor	monoamine oxidase A
Rasagiline mesylate plus Mirapex	Rasagiline mesylate plus Mirapex	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor plus dopamine agonist combination	Monoamine oxidase B and dopamine D2/D3 receptors
Rasagiline mesylate with Levodopa	Rasagiline mesylate with Levodopa	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine precursor	Monoamine oxidase B (MAO-B); Dopamine pathway
Low dose oxelidine group	Low dose oxelidine group	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	Monoamine oxidase inhibitor	Monoamine oxidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine oxidase inhibitor (MAOI) class)

Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FS MDPI — Competitive Intelligence Brief. https://druglandscape.com/ci/fs-mdpi. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab